Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients-a perspective

J Allergy Clin Immunol. 2020 Jul;146(1):58-60. doi: 10.1016/j.jaci.2020.04.043. Epub 2020 May 12.

Authors

Lennart Hammarström¹, Hassan Abolhassani¹, Fausto Baldanti², Harold Marcotte¹, Qiang Pan-Hammarström³

Affiliations

¹ Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden.
² Molecular Virology Unit, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
³ Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden. Electronic address: qiang.pan-hammarstrom@ki.se.

No abstract available

Keywords: COVID-19; IVIG; immunodeficiency; mAb; passive immunity; plasma therapy.

Publication types

Editorial
Comment

MeSH terms

Adult
Betacoronavirus
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections* / drug therapy
Humans
Lopinavir
Pandemics*
Pneumonia, Viral*
Ritonavir
SARS-CoV-2
Severe acute respiratory syndrome-related coronavirus*

Substances

Lopinavir
Ritonavir